Towards advancing cancer nanomedicine: Recent strategies for overcoming translational and toxicological challenges.

The field of nanomedicine holds great promise in healthcare, offering opportunities for precise drug delivery and accurate diagnostic techniques. However, the practical implementation of nanomedicine in clinical settings faces significant barriers. This study critically analyzes the key challenges and proposes innovative approaches to overcome them. The analysis begins by providing a comprehensive explanation of the complex obstacles in translating nanomedicine, with a particular emphasis on the critical need for coordinated regulatory guidelines, nanoformulation design criteria, and the development of standardized preclinical models that accurately simulate clinical scenarios. Additionally, this study investigated the potential toxic impacts of nanocarriers, particularly focusing on issues related to their immunogenicity, cancer biology, and biocompatibility. To enhance the translation process, various innovative solutions, including AI-based drug design, developing next-generation nanomedicines, drug design based on the biology of cancer, merging other advanced technologies, etc., have been suggested. By addressing these challenges, we can expedite the development of safe and effective nanomedicines, ushering in a new era in healthcare.